ArticleJournal of veterinary internal medicine2026
Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSodium-glucose transport 2 inhibitors (SGLT2i) decrease morbidity and mortality in human patients with heart failure through a variety of proposed mechanisms, including natriuresis and glucosuria. The effects of SGLT2i on urine sodium (uNa) and urine glucose (uGlu) concentrations in dogs with heart disease have not been evaluated. HYPOTHESIS/
objectivesAdministration of the SGLT2i dapagliflozin to dogs with heart disease will be well-tolerated and increase uNa and uGlu concentrations. Laboratory results and biomarker assays will provide insight into potential mechanisms of action. ANIMALS: Ten client-owned dogs with heart disease with or without congestive heart failure.
methodsProspective multicenter open-label uncontrolled study. Blood and urine biochemistry and oxidative and inflammatory biomarkers were evaluated at baseline and 5-7 days after 0.45-1 mg/kg/day PO dapagliflozin.
resultsA treatment effect was observed for uGlu (baseline, 14 mg/dL; IQR, 2-19 mg/dL; treatment effect +3102 mg/dL; IQR, 2390-4387 mg/dL; P = .002) but not for uNa (baseline, 75 mmol/L; IQR, 28-129 mmol/L; treatment effect, -41 mmol/L; IQR, -96-21 mmol/L; P = .12). Serum total thiol concentration increased (baseline, 145 μmol/L; SD, 32 μmol/L; treatment effect, +7 μmol/L; SD, 9 μmol/L; P = .04), suggesting an antioxidative effect. Serious adverse effects, including hypoglycemia or ketoacidosis, were not observed. CONCLUSIONS AND CLINICAL IMPORTANCE: Short-term PO dapagliflozin was well-tolerated and associated with glucosuria but not natriuresis. Clinical benefit of SGLT2i in dogs with heart disease might include non-natriuretic mechanisms, such as anti-inflammatory, antioxidative, or metabolic effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.